PAK4 and neoplasm: In a mouse tumor model, the use of KPT-9274, a specific inhibitor of PAK4, or knocking down PAK4 expression, resulted in an increase in cytotoxic T-lymphocyte infiltration within tumors, leading to improved therapeutic outcomes of PD-1 blockade [223].